Biotech Values

[poorgradstudent]

I dont understand why you bring up Tdm1. It is trastzmb plus endocytotic toxin delivery. of course 3 (her2 signaling blockade+ adcc antibody dependent cell mediated cytotoxicity + ADC antibody drug conjugate) is
better than 2 without ADC. the Adcc component of tmab has to be there as blocking her 2 signaling via tki alone could not achieve the same effect as tmab.

Because if ADCC was a meaningful driver, the toxin wouldn't have much of an additional effect.

And again, if ADCC was a meaningful driver, then it would be difficult to explain trastuzumab refractory Her2+ cancer, would it not?

Where else will the backbone antigen PAP of Provenge be expressed after the prostate was out besides PCa cells? Do you not agree an overexpression of target antigen in tumor cell presents a therapeutic window of selective tumor cell killing which is next best to a tumor exclusive antigen.

Quite a few other cell types. And if a genuine immune response is generated that breaks self tolerance, then we know the immune system is rather efficient and it would do a good job of going after the other cells that display detectable expression.